STOCK TITAN

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Kiora Pharmaceuticals (NASDAQ: KPRX) will participate in two upcoming investor conferences. On May 22, at 3:00 pm ET, Executive VP of Finance Melissa Tosca will present at the WeBull Corporate Connect Biotech Investment Webinar. The event will be live and available on-demand for 90 days. On May 30, at 2:45 pm ET, President and CEO Brian Strem will join a virtual fireside chat at the Lytham Partners Spring 2024 Investor Conference. This event will also be live-streamed and available on-demand for 90 days. Kiora's management will hold one-on-one virtual meetings during the Lytham Partners event. Interested parties can arrange meetings by contacting Lytham Partners or registering for the event.

Positive
  • Participation in two investor conferences could increase visibility for Kiora Pharmaceuticals.
  • Presentations by top executives may build investor confidence.
  • Availability of on-demand replays for 90 days provides flexibility for potential investors.
  • One-on-one virtual meetings provide opportunities for personalized investor engagement.
Negative
  • The announcement does not include any significant new product or financial updates.
  • No immediate impact on revenue or profitability is mentioned in the press release.
  • Reliance on investor interest from these events may not guarantee long-term investment.

Encinitas, California--(Newsfile Corp. - May 20, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming investor conferences that will be available to investors live with the replay available on-demand.

On Wednesday May 22, at 3:00 pm Eastern Time, Kiora's Executive Vice President of Finance, Melissa Tosca, will participate in the WeBull Corporate Connect Biotech Investment Webinar. The presentation will be available live from this registration link and the replay will be available on-demand for 90 days on our IR homepage (ir.kiorapharma.com).

On Thursday, May 30, at 2:45 pm Eastern Time, Kiora's President and CEO, Brian Strem, Ph.D., will participate in a virtual fireside chat at the Lytham Partners Spring 2024 Investor Conference. The webcast will be available live from this registration link and the replay will be available on-demand for 90 days on our IR homepage (ir.kiorapharma.com). Management will also be participating in virtual one-on-one meetings throughout the Lytham Partners event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/spring2024invreg/.

About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

In addition to news releases and SEC filings, we expect to post information on our website (www.kiorapharma.com) and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Contacts:

Investors
investors@kiorapharma.com

Media
kiora@crowepr.com
Crowe PR

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/209797

FAQ

When will Kiora Pharmaceuticals participate in the WeBull Corporate Connect Biotech Investment Webinar?

Kiora Pharmaceuticals will participate in the WeBull Corporate Connect Biotech Investment Webinar on May 22 at 3:00 pm ET.

Who will represent Kiora Pharmaceuticals at the Lytham Partners Spring 2024 Investor Conference?

Kiora Pharmaceuticals' President and CEO, Brian Strem, will participate in a virtual fireside chat on May 30 at 2:45 pm ET.

How can investors access the replays of Kiora Pharmaceuticals' presentations?

Replays will be available on-demand for 90 days on Kiora Pharmaceuticals' investor relations homepage.

How can one arrange a meeting with Kiora Pharmaceuticals' management?

To arrange a meeting with Kiora's management, contact Lytham Partners or register for the event.

Kiora Pharmaceuticals, Inc.

NASDAQ:KPRX

KPRX Rankings

KPRX Latest News

KPRX Stock Data

12.34M
2.97M
0.9%
49.25%
1.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ENCINITAS